Sanofi is working to transform the way hemophilia care is delivered in the developing world, where the vast majority of people with the disease have limited or no access to diagnosis and treatment.
Hemophilia is a rare, genetic bleeding disorder in which the ability of a person’s blood to clot is impaired, which can lead to bleeding episodes that can cause pain, irreversible joint damage, and life-threatening hemorrhages. In the developing world, most people with severe hemophilia will not survive to adulthood.
However, things are changing. With support from the World Federation of Hemophilia (WFH) Humanitarian Aid Program, doctors now have access to a predictable and sustainable supply of therapy, which means they are not only able to treat acute and emergency situations, but they also have the capability to perform corrective surgeries and offer prophylactic treatment for young children, something that was unthinkable until now.
As a Founding Visionary Contributor to the WFH Humanitarian Aid Program, with Sobi (an international biopharmaceutical company focused on rare diseases), Sanofi has seen the life-changing impact a predictable and sustainable supply of factor therapy can have.
Bonnie Anderson, Head of Humanitarian Programs at Sanofi noted: “Access to prophylactic treatment for children, and corrective surgeries, are helping to reduce the burden of this disease and provide hope in countries like Vietnam.”
Helping Families with Hemophilia in Vietnam
In 2020, Sanofi, with Sobi, extended its support of the WFH Humanitarian Aid Program with an additional donation of up to 500 million international units (IUs) of factor therapy for humanitarian use, fulfilling the 2014 pledge to donate up to 1 billion IUs of clotting factor over a ten-year period. Since donations began in 2015, Sanofi and Sobi’s medicines have touched the lives of approximately 17,300 people in over 40 developing countries through the program.
“I have witnessed the profound impact that donated factor has on those living with hemophilia in developing countries, and we are grateful to Sanofi and Sobi for their visionary leadership and continued support,” said Alain Baumann, CEO of the WFH.
For lasting change to become a reality, Sanofi will continue collaborating to help address the public health challenges that are too common in the developing world, a mission that goes to the heart of its recently expanded social impact strategy.
About the WFH Humanitarian Aid Program
The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi Genzyme and Sobi, our Founding Visionary Contributors; Bayer and Roche, our Visionary Contributors; Grifols, our Leadership Contributor; and our Contributors, CSL Behring and Takeda. To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org.
MAT-GLB-2101469 V1 04/2021